- Dexcom unveils more clinical data reaffirming the benefits of
Dexcom CGM use among people with Type 2 diabetes than at any
previous ADA conference.
- ADA conference presentations reiterate the advantages of Dexcom
CGM use alongside incretin therapies such as GLP-1s.1,2
- New Dexcom G7 automated insulin delivery integrations* further
solidify the company’s undisputed leadership in CGM
connectivity.
- Recently released Dexcom G7 app updates, including Direct to
Apple Watch,† demonstrate relentless commitment to innovation and
improving user experience.
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring (CGM) for people with diabetes, will
showcase its expanding focus on Dexcom CGM use among people with
Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin
Delivery System with Dexcom G7 and its relentless commitment to
innovation at the 84th Scientific Sessions of the American Diabetes
Association conference held June 21–24, 2024, in Orlando.
Dexcom: The CGM brand for people with Type 2 diabetes,
prediabetes and those using GLP-1s
This year at ADA, Dexcom is presenting more data on Dexcom CGM
use among people with Type 2 diabetes than ever before. This data
shows clinically meaningful decreases in A1C and increases in time
in range for Dexcom CGM users with Type 2 diabetes both on insulin
and not on insulin.3-5
Additionally, studies presented at the conference demonstrate
Dexcom CGM use by people with Type 2 diabetes not on insulin is
associated with improved A1C independent of anti-diabetes
medication, and there may be further benefits of CGM for this
population when used in combination with therapies such as GLP-1s.1
As the use of GLP-1s continues to grow, data continues to show
people with Type 2 diabetes on GLP-1s are more likely to use CGM
after starting the medication.2
Going beyond Type 2 diabetes, another study presented at ADA
demonstrates Dexcom CGM is a valuable behavior modification tool
for people with prediabetes.6 In this study, Dexcom CGM use was
associated with improved self-reported psychosocial health and
self-care behaviors in participants with prediabetes including
perceived benefits related to eating, physical activity, weight,
blood pressure, worry, energy levels and healthcare provider
interactions.
“As the evidence of the benefits of CGM use by people with Type
2 diabetes and prediabetes continues to grow, Dexcom is uniquely
positioned to address their needs through our portfolio of
products,” said Jake Leach, executive vice president and chief
operating officer at Dexcom. “Dexcom G7 is the most accurate and
affordable7 CGM system available for people with Type 1 diabetes
and Type 2 diabetes who use insulin, and when Stelo by Dexcom
launches in late August, we will have a glucose biosensor available
for purchase without a prescription designed specifically for
people with Type 2 diabetes not using insulin.”
Dexcom: The clear choice for automated insulin
delivery
Dexcom further solidified its position as the industry leader in
connectivity this morning with Insulet’s announcement commencing
the launch of the Omnipod 5 with Dexcom G7. Beginning today, new
Omnipod 5 users can experience the benefits of the only tubeless
AID system connected to Dexcom G7, the most accurate CGM7 powering
AID systems. Dexcom G7 will be available for existing Omnipod 5
users in the U.S. later this year.
Dexcom CGM currently connects to more AID pump options than any
other CGM brand in the U.S.; the iLet Bionic Pancreas insulin pump,
the Tandem pump portfolio (Tandem Mobi and t:slim X2 insulin
pumps), and now Omnipod 5. For those seeking more information about
the recent integration of Dexcom G7 and the Tandem Mobi insulin
pump, there will be an evening education event during ADA on June
22, 2024, from 6-8 p.m. Registration is open to U.S. healthcare
provider attendees.
With hundreds of thousands of users now connected to insulin
pumps, pens and digital health apps, Dexcom is the undisputed
leader in CGM connectivity.
Dexcom: A relentless commitment to innovation and customer
experience
For 25 years, Dexcom has been the pioneer in continuous glucose
monitoring, continually innovating on behalf of people with
diabetes. The release of new app updates this month has further
improved the features and user experience of Dexcom G7, the world’s
most accurate CGM system.7
Dexcom G7 is now the first and only CGM with Direct to Apple
Watch connectivity, allowing users to leave their iPhone ‡ behind
and manage diabetes hands-free. It’s now the first and only CGM
with automated activity and medication logging, helping users
visualize how activity and medications affect glucose in real-time.
And with enhanced Bluetooth with Rapid Reconnect, Dexcom G7 now has
65% farther §,8 Bluetooth range and quicker reconnection when
signal is lost, keeping users connected longer.
For a detailed overview of all the Dexcom CGM symposia and
presentations at ADA this year, visit the Dexcom Clinical
Education Resources Microsite.
About DexCom, Inc.
DexCom, Inc. empowers people to take control of health through
innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
on Dexcom, visit https://www.dexcom.com/about.
Category: IR
* To learn more about insulin pump integrations and
compatibility with Dexcom CGM Systems, visit dexcom.com/integrate.
† Smart devices sold separately. For a list of compatible devices,
visit dexcom.com/compatibility. ‡ Compatible smartphone is required
to pair a new Dexcom G7 sensor with a compatible Apple Watch. To
use Share/Follow the smartphone must be within 20 feet of the
Dexcom G7. § Dexcom G7 now has a 33 ft Bluetooth range, 13 feet
farther than the previous 20 ft range.
1 Nemlekar P, Hannah K, Norman GJ. The Combined Effect of CGM
with Antidiabetes Medications and the Association with Improved A1C
in People with Type 2 Diabetes (PWT2D) Not on Insulin Therapy
(NIT). Poster presentation 1914-LB. 2 Wang A, Xu Y, Norman GJ, Reid
JL, Singh H, Yang L. CGM Use in People with Type 2 Diabetes
Initiating GLP-1 or GIP/GLP-1 RA Therapy – Real-World Data. Poster
presentation 1922-LB. 3 Grace T, Layne JE, Hicks C, Green CR,
Walker TC. The Dexcom Community Glucose Monitoring Project for
People with Type 2 Diabetes – One Year Outcomes. Poster
presentation 982-P. 4 Layne JE, Jepson LH, Carite A. Bergenstal RM,
Long-term Improvement in CGM-Measured Glycemic Control in Adults
with Type 2 Diabetes Not Treated with Insulin. Poster presentation
983-P. 5 Norman GJ, Fernandes J, Nemlekar P, Lupton L, Berk A. A1c
Change After Initiating Continuous Glucose Monitoring (CGM) For
People with Diabetes in a Large US Managed Health Care Plan. Oral
presentation 143-OR. 6 Crawford MA, Hicks C, Zhou T, Xu Y, Singh H,
Chernavvasky DR, Levister C, Shah N, Rouviere M, Tamru A, Kaplan L,
Lam DW, O’Malley G, Levy, CL. Value of Dexcom CGM for Therapy
Optimization and Glycemic Outcomes in Post-Hospital Discharge T2D
Patients: An Exploratory Study. Poster presentation 1133-P. 7
Dexcom, data on file, 2024. 8 Dexcom G7 CGM System User Guide.
2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620606764/en/
Media Contact James McIntosh
619-884-2118 james.mcintosh@dexcom.com Investor Contact Sean Christensen 858-203-6657
sean.christensen@dexcom.com
Grafico Azioni DexCom (NASDAQ:DXCM)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni DexCom (NASDAQ:DXCM)
Storico
Da Set 2023 a Set 2024